ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | NDAQ

Overview

Corporate Details

ISIN(s):: US72703U1025 (+1 more)
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
GeneOne Life Science, Inc. Develops nucleic acid vaccines & therapies for infectious diseases, cancer & autoimmune disorders.	South Korea	011000
Generation Bio Co. Developing siRNA genetic medicines via targeted nanoparticles for autoimmune diseases.	United States of America	GBIO
Genetic Analysis AS Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.	Norway	GEAN
GENFIT Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.	France	GNFT
Genfit S.A. Biopharma developing therapeutics and diagnostics for rare and life-threatening liver diseases.	United States of America	GNFT
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.	Türkiye	GENIL
Genmab Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.	Denmark	GMAB
GENMAB A/S Develops innovative antibody therapeutics for cancer and other serious diseases.	United States of America	GMAB
GENOLUTION INC. Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.	South Korea	225220
Genome&Company Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.	South Korea	314130